There is significant crosstalk between DNA damage response (DDR) pathways and innate immune pathways. Both the individual pathways and their interactions are key areas of interest for the development of new small-molecule drug therapeutics targeting cancer and debilitating autoimmune disorders.
The Transcreener HTS Assay platform helps to accelerate these efforts by providing a reliable and user-friendly biochemical assay to measure the activity of critical enzymes involved in the innate immune and DDR pathways.
This eBook will provide an overview of the DDR and innate immune pathway, along with a detailed description of Transcreener Assays and Assay Systems for key therapeutic targets.
Download the full eBook now to learn more
About BellBrook Labs
BellBrook Labs is dedicated to providing the pharmaceutical industry with enabling screening tools to accelerate the discovery of more effective therapies. Leveraging its two base platforms, BellBrook has developed assays for hundreds of drug targets.
